loading...

Severe Asthma Questionnaire (SAQ)

Hyland ME; Jones RC; Lanario JW; Masoli M

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

  • Published in 2018
Authors

Hyland ME; Jones RC; Lanario JW; Masoli M

Copyright
University of Plymouth and University Hospitals Plymouth NHS Trust. All Rights Reserved.
Objective
To measure the burden of asthma symptoms and treatment in severe asthma on health related quality of life
Therapeutic area
  • Respiratory Tract Diseases
  • Immune System Diseases
Therapeutic indication

Asthma

severe asthma
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the UK
Bibliographic reference(s) of the original questionnaire

Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Quality of Life Research. 2015;24:631-9 (PubMed abstract)

Hyland ME, Lanario JW, Pooler J, Masoli M, Jones RC. How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma. Health and quality of life outcomes. 2018;16(1):24 (Full text article)

Hyland ME, Jones RC, Lanario JW, Masoli M. The construction and validation of the Severe Asthma Questionnaire (SAQ). Eur Respir J 2018; 52: 1800618 (Full text article)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

Hyland ME; Jones RC; Lanario JW; Masoli M

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the UK

Translations

The listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

SAQ

Italian for Italy*
Portuguese for Portugal*
* Performed by Mapi

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us